<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Молодежный инновационный вестник</journal-id><journal-title-group><journal-title>Молодежный инновационный вестник</journal-title></journal-title-group><issn publication-format="print">2415-7805</issn><publisher><publisher-name>Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11532</article-id><article-categories><subj-group subj-group-type="heading"><subject>Conference Proceedings</subject></subj-group></article-categories><title-group><article-title>Treatment and prevention of migraines with the use of hepants</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Frolov</surname><given-names>Vasiliy  Kirillovich</given-names></name><email>vasiafrolov2019@gmail.com</email><uri content-type="orcid">https://orcid.org/0009-0002-4895-0251</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khuranov</surname><given-names>Amal Amirovich</given-names></name><email>huranov180505@icloud.ru</email><uri content-type="orcid">https://orcid.org/0009-0008-5121-9148</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rusanovsky</surname><given-names>Vladimir Vasilievich</given-names></name><bio>&lt;p&gt;MD, Professor of the Department of Pharmacology with a course in Clinical Pharmacology and Pharmacoeconomics&lt;/p&gt;</bio><email>rusvv2058@mail.ru</email><uri content-type="orcid">https://orcid.org/0000-0002-0432-7946</uri><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">Saint Petersburg State Pediatric Medical University</aff><pub-date date-type="epub" iso-8601-date="2026-10-01" publication-format="electronic"><day>01</day><month>10</month><year>2026</year></pub-date><volume>15</volume><issue>S1</issue><fpage>443</fpage><lpage>444</lpage><history><pub-date date-type="received" iso-8601-date="2026-03-16"><day>16</day><month>03</month><year>2026</year></pub-date><pub-date date-type="accepted" iso-8601-date="2026-04-08"><day>08</day><month>04</month><year>2026</year></pub-date></history><permissions><copyright-statement>Copyright © 2026, Frolov V.K., Khuranov A.A., Rusanovsky V.V.</copyright-statement><copyright-year>2026</copyright-year></permissions><abstract>&lt;p style="text-align: justify;"&gt;&lt;span class="TextRun SCXW46526598 BCX8" lang="EN-US" xml:lang="EN-US" data-contrast="auto"&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация" data-ccp-parastyle-defn="{ObjectId:69275384-78e1-5250-98e2-bdff8b0065a5|1,ClassId:1073872969,Properties:[268442635,24,335559704,1025,335559705,1033,335551547,1049,335559740,276,201341983,0,335559739,0,469777841,Times New Roman,469777842,Arial,469777843,游明朝,469777844,Times New Roman,469769226,Times New Roman,游明朝,469775450,5-Аннотация,201340122,2,134234082,true,134233614,true,469778129,style4106,335572020,0,134224901,true,335559731,709,335559738,240,335551550,6,335551620,6,134233279,true,469777929,5-Аннотация Знак,469775498,6-Ключевые слова,469778324,Normal]}" data-ccp-parastyle-linked-defn="{ObjectId:3bb584b9-b152-5ad4-89f2-c9a98b641f06|1,ClassId:1073872969,Properties:[469777841,Times New Roman,469777842,Arial,469777843,游明朝,469777844,Times New Roman,469769226,Times New Roman,游明朝,469775450,5-Аннотация Знак,201340122,1,134233614,true,469778129,style4118,335572020,0,134231262,true,134224901,true,268442635,24,469777929,5-Аннотация,469775498,5-Аннотация Знак,469778324,Default Paragraph Font]}"&gt;Currently, migraine ranks as the second leading cause of years&lt;/span&gt;&lt;span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;lived&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;with disability worldwide,&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;predominantly affecting&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;individuals of working age.&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;For many years, specific treatment options were limited to triptans, which have significant drawbacks, including contraindications in patients with cardiovascular risks and reduced efficacy when administered late after attack onset.&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;A major advance in understanding migraine pathogenesis was the discovery of the pivotal role of calcitonin gene-related peptide (CGRP). This finding led to the development of monoclonal antibodies; however, their use is limited by the need for injections and&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;high costs&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;.&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;Gepants&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;, which are small molecules that block CGRP receptors, have&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;emerged&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;as a promising alternative. These agents do not cause vasoconstriction and have proven effective both for acute treatment and preventive therapy. The aim. To review and summarize current evidence on the mechanism of action, efficacy, and safety of&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;gepants&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;based on recent clinical studies. Materials and methods. An analysis of international scientific literature available in the PubMed, Scopus, and Cochrane Library databases was performed. Results. The analysis confirmed that&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;gepants&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;selectively block CGRP receptors on trigeminal nerves without affecting coronary artery tone. In clinical trials,&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;rimegepant&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;(75 mg) was significantly more effective than placebo in achieving pain freedom two hours after dosing (21.3% vs. 10.9%). Ubrogepant (50 mg)&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;maintained&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;a favorable safety profile with intermittent use up to eight times per month. Adverse effects were&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;generally mild&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;, including nausea and dry mouth, and did not lead to&lt;/span&gt;&lt;span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;treatment&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;discontinuation.&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;Atogepant&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;, approved for migraine prevention, reduced mean monthly migraine days by 4.2 days compared to baseline in a 52-week study. Conclusions.&lt;/span&gt;&lt;span class="NormalTextRun SpellingErrorV2Themed SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt;Gepants&lt;/span&gt;&lt;span class="NormalTextRun SCXW46526598 BCX8" data-ccp-parastyle="5-Аннотация"&gt; offer an effective and safe alternative to triptans and monoclonal antibodies for migraine patients. Their oral administration and lack of vasoconstrictor effects broaden therapeutic options, particularly for individuals with concomitant cardiovascular conditions.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</abstract><kwd-group xml:lang="en"><kwd>migraine</kwd><kwd>medications</kwd><kwd>tone</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мигрень</kwd><kwd>препараты</kwd><kwd>тонус</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Moreno-Ajona, D. New oral drugs for migraine: gepants and ditans / D. Moreno-Ajona, M. D. Villar-Martínez, P. J. Goadsby // Cephalalgia. — 2023. — Vol. 43, № 4. — P. 03331024231159499.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ailani, J. Atogepant for the preventive treatment of migraine: a 52 week open-label study / J. Ailani, R. B. Lipton, P. J. Goadsby [et al.] // Neurology. — 2021. — Vol. 97, № 19. — P. e1890-e1901.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hargreaves, R. Calcitonin gene-related peptide modulators: the journey from the tip of a cone to the clinic / R. Hargreaves, J. Olesen // Headache: The Journal of Head and Face Pain. — 2024. — Vol. 64, № 1. — P. 5-16.</mixed-citation></ref></ref-list></back></article>
